BIOMUNEX has a strong IP position. Many priority patent applications cover the platform and products; new products and inventions on the BiXAb® technology are covered by additional IP, providing further protection to BIOMUNEX inventions. Various patent applications were filed by BIOMUNEX: 

  • several patent applications on the BiXAb® Platform. 
  • several patent applications for its BiXAb® lead products with the objective of protecting all BIOMUNEX’ proprietary antibodies. 

BiXAb® bi- and multi-specific technology has been originally developed based on a multi-specific format licensed by BIOMUNEX from a pan-European academic Consortium.  

BIOMUNEX is actively developing new intellectual property based on its own R&D efforts and in collaboration with academic teams and industrial partners.